The potential of more affordable diabetic care comes in the wake of Swiss major Novartis-owned Vildagliptin losing patent on Monday — a development closely watched for months. Dozens of companies have readied plans to get a slice of the action in the growing Rs 14,000-crore diabetes therapy market, with the number of players expected to cross 50 soon.
source https://timesofindia.indiatimes.com/business/india-business/price-of-diabetes-drug-to-halve-soon/articleshow/72448740.cms
Monday, 9 December 2019
Subscribe to:
Post Comments (Atom)
This blog is truly useful to convey overhauled instructive undertakings over web which is truly examination. I discovered one fruitful case of this truth through this blog. I will utilize such data now.Benfotiamine
ReplyDelete